To further examine the association between this polymorphism and the risk of breast cancer, we analyzed the prevalence of this variant in a series of 507 patients with two primary breast cancers and 875 healthy control subjects. We specifi cally selected patients with two breast cancers for inclusion in this study because association studies based on cancer patients with a family history of the disease or with multiple primary cancers have greater power to detect cancer susceptibility genes than studies of unselected patients, most of whom have a single primary breast cancer and no family history ( 9 , 10 ) .
STK15 may be a low-penetrance breast cancer susceptibility gene, and several reports suggest that women who are homozygous for the polymorphic variant F31I have an increased risk of breast cancer. To evaluate this potential breast cancer allele, we genotyped 507 patients with two primary breast cancers and 875 populationbased control subjects for the STK15 F31I polymorphism. All statistical tests were two-sided. The Ile/Ile homozygous genotype was not associated with an increased risk in white women of British descent. The odds ratio for developing two primary breast cancers) in Ile/Ile homozygotes was 0.63 (95% confi dence interval [CI] = 0.34 to 1.13), which corresponds to an odds ratio of 0.79 (95% CI = 0.58 to 1.06) for a fi rst primary breast cancer. A meta-analysis of this study and other published studies showed statistically signifi cant heterogeneity in the odds ratio estimates ( P <.001). This heterogeneity could refl ect either populationspecifi c linkage disequilibrium with a functional variant or artifacts such as population stratifi cation or publication bias. [J Natl Cancer Inst 2006;
98: 1014 -8 ]
The STK15 gene encodes a serine/ threonine kinase that acts as a key regulator of mitotic chromosome segregation ( 1 , 2 ) . Studies in transgenic mice have suggested that STK15 is a candidate low-penetrance tumor susceptibility gene ( 3 ) , and analyses of archival tumor blocks ( 4 ) and experiments examining the role of the STK15 gene in chromosome segregation have provided compelling evidence that STK15 has a role in the etiology of cancer. A single-nucleotide polymorphism in the STK15 gene, T91A, results in the polymorphic substitution of isoleucine (Ile) for phenylalanine (Phe) at residue 31 (F31I) ( 3 ) . Several reports ( 5 -8 ) suggest that women who are homozygous for the Ile/Ile allele have an increased risk of breast cancer.
To further examine the association between this polymorphism and the risk of breast cancer, we analyzed the prevalence of this variant in a series of 507 patients with two primary breast cancers and 875 healthy control subjects. We specifi cally selected patients with two breast cancers for inclusion in this study because association studies based on cancer patients with a family history of the disease or with multiple primary cancers have greater power to detect cancer susceptibility genes than studies of unselected patients, most of whom have a single primary breast cancer and no family history ( 9 , 10 ) .
Our case patients were women with two primary breast cancers who were identifi ed through the English Cancer Registries, as previously described ( 11 ) . 448 (88.4%) of our case patients had bilateral disease and 59 (11.6%) had developed a later second primary cancer in the same breast. Control subjects were non-blood female relatives and friends of the case patients ( n = 382) and women who were recruited from mammography for a fi rst primary breast cancer among homozygotes (Ile/Ile) from this study (ψ U = 0.79, which we calculated as the square root of ψ B = 0.63, our observed odds ratio in cases with two primary breast cancers, see Appendix I) and from the other published series of unselected cases ( 5-8 , 12 ) . However, the pooled odds ratio for all studies combined (OR = 1.19, 95% CI = 0.96 to 1.48) is diffi cult to interpret because the odds ratio estimates in the different studies were heterogeneous (Cochran's Q = 20.47, P <.001, I 2 = 75.6%). When we conducted separate meta-analyses for the three Asian studies ( 7, 8, 12 ) and for our data and the two non-Asian studies ( 5, 6 ), we still found evidence of between-study heterogeneity, particularly among the Asian studies (Asian studies: Cochran's Q = 12.2, P = .002, I 2 = 83.6%; nonAsian studies: Cochran's Q = 7.41, P = .03, I 2 = 73.0%). The Asian populations may not be genetically similar, because the Ile/Ile homozygote frequency was statistically signifi cantly lower in Han Chinese control subjects ( 7 ) than in Shanghai Chinese control subjects ( 8, 12 ) (36.9% versus 45.0%, difference = 8.1%, 95% CI = 3.1% to 13.1%; P = .002, Fisher's exact test). There may also be genetic differences among populations in the non-Asian studies. The case patients and control subjects in our study were white English residents, whereas the North American subjects studied by Egan et al. clinics in England ( n = 493). Written informed consent was obtained from all study subjects. This study was approved by the South East Multi-centre Research Ethics Committee. All women reported being white and of British descent. DNA from case patients and control subjects was extracted from peripheral blood lymphocytes using a QIAmp DNA Blood Mini kit (Qiagen, Sussex, United Kingdom). Case patients and control subjects were genotyped for the STK15 T91A single-nucleotide polymorphism (rs2273535) by a polymerase chain reaction-restriction fragment length polymorphism assay that used the restriction enzyme ApoI. This polymorphism has a minor allele frequency of 21% in Europe an control populations, resulting in a rare homozygote frequency of 4.4% ( 5 , 6 ) . Primer sequences and reaction conditions used for genotyping SKT15 are available at http://jncicancerspectrum.oxford journals.org/jnci/content/vol98/issue14 .
If a second breast cancer arises independently of the fi rst primary, the odds ratio (OR) for having two primary tumors in carriers of a susceptibility genotype ( ψ B ) is approximately the square of the odds ratio ( ψ U ) for unselected fi rst primary cancers ( 9 ) . However, if women who have developed a fi rst breast cancer are at increased risk for nongenetic reasons (e.g., environmental risk factors, or, conceivably, a somatic effect of the fi rst cancer), the square root is not the appropriate transformation from ψ B to ψ U . We have used the square root transformation and presented our results in terms of ψ U to make our results compatible with those from other studies, but our statistical conclusions are virtually unaffected by this convention (see Appendix I ). Odds ratios with 95% confi dence intervals (CIs) were calculated using the STATA statistical package (version 8.0; Stata Corporation, College Station, TX). All statistical tests were two-sided.
We found that the Ile/Ile homozygous genotype did not confer an increased risk for developing two primary breast cancers (number of case patients by genotype: Phe/Phe, N = 335; Phe/Ile, N = 154; Ile/Ile, N = 18; number of control subjects by genotype: Phe/Phe, N = 547; Phe/Ile, N = 280, Ile/Ile, N = 48; OR [ ψ B ] = 0.63, 95% CI = 0.34 to 1.13). Because there was no a priori reason to assume a recessive effect of STK15 F31I on breast cancer risk, we also estimated the multiplicative risk per allele by fi tting a codominant model. The resulting estimates of the odds ratio for fi rst primary cancers in Ile/Ile homozygotes were 0.79 (95% CI = 0.58 to 1.06) under a recessive model and 0.85 (95% CI = 0.70 to 1.03) under a codominant model. Both upper 95% confi dence limits were close to unity. Thus, although we cannot rule out a positive association between STK15 F31I and the risk of breast cancer in other populations, we conclude that this association is negligible or negative in English women regardless of the mode of genetic transmission.
To combine our data with that of other published studies, we searched PubMed and EMBASE databases using the keywords " stk15, " " aurora, " " aurka, " and " BTAK " alone or in combination with " breast cancer " or " case -control " or " cohort " for English language articles published between January 1, 1966, and October 31, 2005. Reference lists within all relevant articles and reviews were searched to identify publications not captured by the computerized searches. This search identifi ed only fi ve studies ( 5 -8 , 12 ) , three of which were conducted among Asian populations. We calculated Cochran's Q statistic ( 13 ) to test for heterogeneity among the odds ratio estimates for the studies and the I 2 statistic ( 14 ) to quantify between-study variation. Because there was evidence of statistically signifi cant heterogeneity between studies, we used a randomeffects model to estimate the combined odds ratio ( 15 ) . Fig. 1 and Table 1 show estimates under a recessive model of the odds ratio † Power calculations were for detecting an odds ratio of 1.5 for rare homozygotes ( I / I ) versus all other genotypes ( F / I + F / F ) at statistical signifi cance levels of 5% and 1%. Calculations were based on a rare homozygote frequency of 40% in Asian populations and 4.4% in non-Asian populations ( 5 -8,12 ) . ‡ For the data from our series, the ORs and 95% CIs shown are the square roots of the values for case patients with two primary cancers.
This heterogeneity among the published studies in our meta-analysis could also refl ect population-specifi c linkage disequilibrium between the STK15 F31I polymorphism and another functional variant in STK15 or in another gene. Lo et al. ( 8 ) suggested that the F31I polymorphism in the Taiwanese population in their study was in linkage disequilibrium with a more extended haplotype that was associated with breast cancer risk. If this was the case, then the F31I polymorphism might be associated with increased breast cancer risk in some populations and with reduced risk in others. A less interesting, but perhaps more plausible, explanation for the heterogeneity among studies is an artifact such as population stratifi cation or publication bias. The odds ratio estimate from the fi rst published report of a genetic association is often greater than estimates reported in subsequent studies ( 16 , 17 ) . The fi rst published study of STK15 F31I in breast cancer ( 7 ) reported a statistically signifi cant association (OR = 1.66, 95% CI = 1.28 to 2.14). When we excluded this study from the metaanalysis, the combined odds ratio estimate for the fi ve remaining studies was not statistically signifi cantly greater than unity (OR = 1.09, 95% CI = 0.90 to 1.31) and the between-study heterogeneity was reduced, although still just statistically signifi cant (Cochran's Q = 10.00, P = .04, I 2 = 60.0%).
An important advantage of association studies of women with two primary breast cancers patients is the gain in statistical effi ciency. Table 2 shows that the reduction in sample size that can be achieved by studying bilateral breast cancers ranges from fourfold to more than fi vefold depending on the relative risk, the allele frequency, and the genetic model. Under a polygenic model for breast cancer susceptibility, a large number of genes that individually confer low risks act in combination, resulting in a wide spectrum of risk in the population. To reliably identify individuals who are at high risk of breast cancer, it may be necessary to detect large numbers of relevant " polygenes " that confer odds ratios as low as 1.2. If the true odds ratio in homozygotes were 1.2, the number of bilateral case patients needed to detect a single nucleotide polymorphism such as STK15 T91A with a minor allele frequency of approximately 0.2 would be 2100 for a codominant effect or 4000 for a recessive effect. The corresponding numbers of unselected case patients that would be required would be 8600 (codominant) and 17 100 (recessive). Moreover, an observed odds ratio of 1.2 in a large study of unselected case patients could be due to the combined effects of chance and the biases inherent in genetic epidemiology. A gene that conferred an odds ratio of 1.2 for a fi rst primary breast cancer would give an odds ratio of more than 1.4 in breast cancer patients with two primaries, which because of its greater magnitude would be less likely to be the result of such biases. Population-based studies of familial breast cancer cases or cases with two primaries also have other advantages. For example, a trend in the prevalence of the risk allele with an increasing number of affected relatives, as was seen for the 1100delC allele of the CHEK2 gene ( 18 ) , provides independent evidence of a real genetic effect. Moreover, the cancer rate in relatives of breast cancer patients with two primaries may indicate whether a risk allele interacts Table 2 . Numbers of unselected breast cancer cases and cases with two primary breast cancers required to detect odds ratios of 1.2 to 2.5 associated with a susceptibility allele, assuming a case patient/control subject ratio of 1:1, 80% statistical power, and 1% level of statistical signifi cance * OR ( ψ U ) (homozygotes versus noncarriers) * Under the recessive model only rare homozygotes are at increased risk, whereas under the multiplicative codominant model the odds ratio (OR) in heterozygotes is the square root of that in rare homozygotes. The range of ORs chosen refl ects those reported for low-penetrance breast cancer alleles (e.g., TP53 Arg72Pro: OR = 1.27, 95% confi dence interval [CI] = 1.02 to 1.59; GSTP1: OR = 1.60, 95% CI = 1.08 to 2.59; CHEK2*1100delC: OR = 2.34, 95% CI = 1.72 to 3.20) ( 18, 21 ) . multiplicatively or additively with other undiscovered genes ( 11 ) .
